Clinical trials: Hepatic Disease
Non-alcoholic Steatohepatitis (NASH)
A Study of the Efficacy and Safety of CF102 in the Treatment of Non-Alcoholic Fatty Liver Disease
This is a multicenter, randomized, double-blind, placebo-controlled clinical trial in subjects with NAFLD and NASH.
- Trial name
- NCT02927314
- Testing
- CF102
- Where
- 3 sites in Israel
- Volunteers
- 60 people
- Sponsor
- Can-Fite BioPharma
Hepatitis C, Hepatitis C, Chronic
Thymosin Plus PEG-Interferon in Non-Cirrhotic Hepatitis C Patients Who Did Not Respond to Interferon or Interferon Plus Ribavirin
Chronic hepatitis C infection is one of the leading causes of chronic liver disease in the United States. Approximately one-third of patients with hepatitis C infection develop cirrhosis of the liver, which can lead to liver…
- Trial name
- NCT00040027
- Testing
- thymalfasin (thymosin alpha 1) + PEGinterferon alfa-2a
- Where
- 48 sites in United States, Puerto Rico
- Volunteers
- 500 people
- Sponsor
- SciClone Pharmaceuticals
Hepatocellular Carcinoma, Prostate Cancer
LTFU for All Cell and Gene Therapy Studies
Master LTFU study will monitor the long-term safety and tolerability of cell or gene therapy study participants from AstraZeneca for up to 15 years post last cell or gene therapy treatment.
- Trial name
- LOCUS (NCT06194461)
- Testing
- AZD5851, AZD0754
- Where
- 25 sites in United States, Australia and 2 more
- Volunteers
- 64 people
- Sponsor
- AstraZeneca
Tumor
A Study Evaluating the Drug Levels of Iplimumab Given Under the Skin Alone and in Combination With Nivolumab in Multiple Tumor Types
A study evaluating the drug levels of ipilimumab alone and in combination with nivolumab applied under the skin in various tumor types
- Trial name
- CheckMate 76U (NCT04311710)
- Testing
- ipilimumab, nivolumab, ENHANZE (rHuPH20)
- Where
- 6 sites in United States, Italy and 1 more
- Volunteers
- 21 people
- Sponsor
- Bristol-Myers Squibb
Hypoalbuminemia, Hepatic Cirrhosis
A Study to Evaluate the Efficacy and Safety of OsrHSA in Patients of Hepatic Cirrhosis With Hypoalbuminemia
The goal of this clinical trial is to evaluate the efficacy of OsrHSA works to treat hypoalbuminemia in hepatic cirrhosis patients. It will also learn about the safety and immunogenicity of OsrHSA.
- Trial name
- NCT06355479
- Testing
- OsrHSA, Plasbumin®-20
- Where
- 37 sites in China
- Volunteers
- 328 people
- Sponsor
- Healthgen Biotechnology Corp.
Chronic Hepatitis C Infection
A Study to Evaluate the Safety and Effect of the Experimental Drugs ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 in Subjects With Chronic Hepatitis C
The purpose of this study is to evaluate the safety and antiviral activity of ABT-450/ritonavir/ABT-267 (ABT-450/r/ABT-267; ABT-450 also known as paritaprevir; ABT-267 also known as ombitasvir) and ABT-333 (also known as…
- Trial name
- PEARL-II (NCT01674725)
- Testing
- ABT-450/r/ABT-267, ABT-333, Ribavirin
- Volunteers
- 187 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Hepatitis C, HCV
VX-950-TiDP24-C134: Drug-drug Interaction Trial Between Combination of Efavirenz and Tenofovir Disoproxil Fumarate and Different Dosages of Telaprevir on Healthy Volunteer
The purpose of this study is to determine the effect of EFV (Efavirenz) and TDF (Tenofovir disoproxil fumarate) on the pharmacokinetics of TVR (Telaprevir) and to determine the effect of TVR on the pharmacokinetics of EFV and…
- Conditions
- Hepatitis C, HCV, HIV, AIDS
- Trial name
- NCT00828789
- Testing
- Efavirenz; Tenofovir disoproxil fumarate; Telaprevir
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Tibotec BVBA
Pulmonary Disease, Chronic Obstructive
A Study to Assess the Effects of GSK573719/VI Combination and GSK573719 Monotherapy in Subjects With Moderate Hepatic Impairment and Matched Healthy Volunteers
This study will assess the safety and pharmacokinetics of GSK573719 and GSK573719/vilanterol combination in healthy subjects and subjects with moderate hepatic impairment.
- Trial name
- NCT01577680
- Testing
- Inhaled GSK573719/vilanterol, Inhaled GSK573719
- Where
- 2 sites in Hungary, Slovakia
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Hepatocellular Carcinoma
Study of TAC-101 as Second Line Treatment in Patients With Advanced Hepatocellular Carcinoma Who Received Sorafenib as First Line Therapy
The purpose of this study is to determine whether TAC-101 as a second line therapy for participants who received Sorafenib as first line therapy is effective in slowing tumor activity in patients with advanced hepatocellular…
- Trial name
- NCT00687596
- Testing
- TAC-101
- Where
- Italy
- Volunteers
- 52 people
- Sponsor
- Taiho Oncology, Inc.
Fatty Liver
The Effect of a Probiotic on Hepatic Steatosis
Non-alcoholic fatty liver disease (NAFLD) is an accumulation of fat and fibrous tissue in the liver. It is the most common cause of chronic liver disease in the United States.
- Trial name
- NCT00099723
- Testing
- VSL#3
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- VSL Pharmaceuticals
Hepatitis C Virus
Ph IIA Study (SOC +/- NS5B)
At least 1 dose of BMS-791325 can be identified which is safe, well tolerated, and efficacious when combined with peg-interferon alfa-2a (pegIFNα-2a)/ribavirin (RBV) for the treatment of treatment-naïve, chronically-infected…
- Trial name
- HEPCAT (NCT01193361)
- Testing
- BMS-791325, Peg-interferon alfa-2a, Ribavirin
- Where
- 10 sites in United States
- Volunteers
- 39 people
- Sponsor
- Bristol-Myers Squibb
Chronic Hepatitis C
Efficacy and Safety of MP-424, Peginterferon Alfa-2b, and Ribavirin in Patients With Chronic Hepatitis C Who Relapsed After Previous Interferon Based Therapy
This study will evaluate the efficacy and safety of MP-424 with Peginterferon Alfa-2b (PEG-IFN) and Ribavirin (RBV) in patients with (Genotype 1) hepatitis C, who relapsed after previous treatment.
- Trial name
- NCT00780910
- Testing
- MP-424, Ribavirin, Peginterferon Alfa-2b
- Where
- Japan
- Volunteers
- 109 people
- Sponsor
- Tanabe Pharma Corporation
Chronic Liver Disease
Prediction Value of the BreathID 13C-Methacetin Breath Test for Hepatic Decompensation
The objectives of this study are: To evaluate the ability of the Methacetin Breath Test (MBT) to detect hepatic decompensation events To evaluate the relationship between liver Biopsy and clinical outcome and show that the MBT…
- Trial name
- NCT02084160
- Where
- 4 sites in United States, Israel
- Volunteers
- 579 people
- Sponsor
- Meridian Bioscience, Inc.
Hepatitis C
Dose Escalation Study of IL-7 and Bi-therapy in HCV Patients Resistant After 12 Weeks of Bi-therapy (ECLIPSE 1)
This study will evaluate the safety of a new experimental drug, IL-7, in people with HCV infection resistant after 12 weeks of bi-therapy.
- Trial name
- ECLIPSE 1 (NCT01025596)
- Testing
- Interleukin-7
- Where
- 7 sites in France, Italy and 1 more
- Volunteers
- 10 people
- Sponsor
- Cytheris SA
Locally Advanced Tumor, Metastatic Solid Tissue Tumors
Safety and Efficacy Study of DCVax-Direct in Solid Tumors
The study comprises a Phase I component during which the optimal dose of DCVax-Direct for the treatment of solid tissue tumors will be identified, followed by a Phase II component to determine if the injection of DCVax-Direct…
- Conditions
- Locally Advanced Tumor, Metastatic Solid Tissue Tumors, Liver Cancer, Colorectal Cancer
- Trial name
- NCT01882946
- Testing
- DCVax-Direct
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- Northwest Biotherapeutics
Hepatitis C
Efficacy and Safety of Narlaprevir Used in Combination With Ritonavir in Treatment-Naïve and Failed Prior Treatment With Pegylated Interferon/Ribavirin Patients With Chronic Hepatitis C Genotype 1 (PIONEER - Study)
The purpose of this study was to confirm that combination of narlaprevir (NVR) and ritonavir (RTV) used as a metabolic inhibitor with pegylated interferon (PEG-INF) and ribavirin (RBV) leads to a superior Sustained Virological…
- Trial name
- PIONEER (NCT03833362)
- Testing
- Narlaprevir, Ritonavir, Pegylated interferon alfa-2a/ Pegylated interferon alfa-2b
- Where
- 20 sites in Russia
- Volunteers
- 420 people
- Sponsor
- R-Pharm
Chronic Hepatitis B
Therapeutic Hepatitis B Vaccine (Mimogen-based) Joint Entecavir in Treating Chronic Hepatitis B Patients
The purpose is to evaluate efficacy and safety of therapeutic hepatitis B virus (HBV) vaccine (mimogen-based)) Joint entecavir treatment in chronic hepatitis B patients.
- Trial name
- NCT01326546
- Testing
- Therapeutic HBV vaccine, entecavir
- Where
- 15 sites in China
- Volunteers
- 378 people
- Sponsor
- Chongqing Jiachen Biotechnology Ltd.
Hepatitis B, Chronic
Lamivudine(LAM) Good Responder Study
This is to evaluate the proportion of subjects who show good responses to LAM treatment in Korea.
- Trial name
- LAMGR (NCT01128686)
- Testing
- No intervention
- Where
- South Korea
- Volunteers
- 1 people
- Sponsor
- ViiV Healthcare
Hepatitis C, Chronic
PEG-IFN Alfa-2b Plus Ribavirin for Treatment of Mexican naïve Patients With Chronic Hepatitis C Infected With Genotype 1 (Study P04511)(COMPLETED)
This study aims to evaluate the efficacy and safety of peginterferon alfa-2b plus weight-based ribavirin as initial treatment in chronic hepatitis C virus (HCV) genotype 1 patients.
- Trial name
- NCT00724620
- Testing
- Peginterferon alfa-2b (SCH 054031), Ribavirin (SCH 018908)
- Volunteers
- 103 people
- Sponsor
- Schering-Plough
Hepatitis B, Chronic
Evaluate the Efficacy and Safety of HLX10 in Chronic Hepatitis B Patients
A multiple-center, open-label, Phase II clinical trial to evaluate the safety and the efficacy of HLX10 in chronic hepatitis B patients.
- Trial name
- NCT04133259
- Testing
- Recombinant anti-programmed death-1 (PD-1) humanized monoclonal antibody, Nucleoside/nucleotide analogues
- Where
- 3 sites in Taiwan
- Volunteers
- 44 people
- Sponsor
- Henlix, Inc
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.